Chicago Partners Investment Group LLC Makes New $64,000 Investment in Rein Therapeutics Inc. $RNTX

Chicago Partners Investment Group LLC purchased a new position in Rein Therapeutics Inc. (NASDAQ:RNTX) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 41,242 shares of the company’s stock, valued at approximately $64,000. Chicago Partners Investment Group LLC owned about 0.19% of Rein Therapeutics at the end of the most recent quarter.

Separately, Blair William & Co. IL purchased a new position in Rein Therapeutics in the second quarter worth $33,000. Institutional investors and hedge funds own 90.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on RNTX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Rein Therapeutics in a report on Saturday. HC Wainwright started coverage on shares of Rein Therapeutics in a report on Monday, September 22nd. They set a “buy” rating and a $10.00 price objective on the stock. Finally, Brookline Capital Management lowered shares of Rein Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 19th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $10.00.

Rein Therapeutics Price Performance

NASDAQ RNTX opened at $1.44 on Friday. The company has a market capitalization of $33.56 million, a PE ratio of -0.54 and a beta of 1.14. The company has a fifty day moving average of $1.23 and a 200 day moving average of $1.50. Rein Therapeutics Inc. has a 1 year low of $1.04 and a 1 year high of $4.40.

Rein Therapeutics (NASDAQ:RNTX) last posted its earnings results on Thursday, August 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). Research analysts expect that Rein Therapeutics Inc. will post -1.56 earnings per share for the current year.

About Rein Therapeutics

Rein Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers.